

해외 바이오의약품 임상 현황 (2020.10.26~2020.11.1)

한국바이오의약품협회, 2020.11.3
출처: ClinicalTrials.gov

○ 미국 77건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04610658	Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC	Small-cell Lung Cancer Relapsed Small Cell Lung Cancer Recurrent Small Cell Lung Cancer	Drug: Nivolumab Drug: Ipilimumab Drug: Lurbinectedin	H. Lee Moffitt Cancer Center and Research Institute Bristol-Myers Squibb PharmaMar	Phase 1 Phase 2
NCT04588545	Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease	HER2-positive Breast Cancer Leptomeningeal Metastasis Leptomeningeal Disease	Radiation: Radiation Therapy Drug: Pertuzumab Drug: Trastuzumab	H. Lee Moffitt Cancer Center and Research Institute Genentech, Inc.	Phase 1 Phase 2
NCT04570501	Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients	Covid19	Drug: Angiotensin-(1-7) Drug: Placebo	Stanford University	Phase 1 Phase 2
NCT04563195	BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome	Primary Sjogren's Syndrome	Drug: tibulizumab (LY3090106)	Matthew C. Baker Stanford University	Phase 2 Phase 3
NCT04331067	Cabiralizumab in Combination With Nivolumab and Neoadjuvant Chemotherapy in Patients With Localized Triple-negative Breast Cancer	Triple Negative Breast Cancer	Drug: Paclitaxel Drug: Carboplatin Biological: Nivolumab Biological: Cabiralizumab Procedure: Tumor biopsy Procedure: Bone marrow Procedure: Blood draw	Washington University School of Medicine Bristol-Myers Squibb	Phase 1 Phase 2
NCT04257578	Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma	B-Cell Non-Hodgkin Lymphoma Diffuse Large B-Cell Lymphoma, Not Otherwise Specified High Grade B-Cell Lymphoma Primary Mediastinal (Thymic) Large B-Cell Lymphoma Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma	Drug: Acalabrutinib Biological: Axicabtagene Ciloleuce	University of Washington National Cancer Institute (NCI) AstraZeneca	Phase 1 Phase 2
NCT04060407	CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)	Metastatic Melanoma Renal Cell Carcinoma Colon Cancer With MSI-H or dMMR	Drug: CD24Fc Drug: Ipilimumab Drug: Nivolumab	Oncolmmune, Inc. Huntsman Cancer Institute	Phase 1 Phase 2
NCT04606784	Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress	Covid19	Biological: Ampion Other: Standard of Care	Ampio Pharmaceuticals, Inc.	Phase 1
NCT04606576	Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus	Type 2 Diabetes Mellitus	Other: Placebo Drug: ORMD-0801 QD Drug: ORMD-0801 BD	Oramed, Ltd. Integrium	Phase 3
NCT04605731	Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer	BCLC Stage B Hepatocellular Carcinoma BCLC Stage C Hepatocellular Carcinoma Locally Advanced Hepatocellular Carcinoma Stage III Hepatocellular Carcinoma AJCC v8 Stage IIIA Hepatocellular Carcinoma AJCC v8 Stage IIIB Hepatocellular Carcinoma AJCC v8 Stage IV Hepatocellular Carcinoma AJCC v8 Stage IVA Hepatocellular Carcinoma AJCC v8 Stage IVB Hepatocellular Carcinoma AJCC v8 Unresectable Hepatocellular Carcinoma	Biological: Durvalumab Biological: Tremelimumab	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1
NCT04605614	64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression	Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm	Radiation: Copper Cu 64-DOTA-pembrolizumab Biological: Pembrolizumab Procedure: Positron Emission Tomography	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1
NCT04594707	A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	Drug: PRM-151	Hoffmann-La Roche	Phase 3
NCT04588038	NT-17 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery	Recurrent Head and Neck Squamous Cell Carcinoma Recurrent Hypopharyngeal Squamous Cell Carcinoma Recurrent Laryngeal Squamous Cell Carcinoma Recurrent Oral Cavity Squamous Cell Carcinoma Recurrent Oropharyngeal Squamous Cell Carcinoma Resectable Oropharyngeal Squamous Cell Carcinoma	Biological: Efinetakin alfa	Hyunseok Kang, MD NeolmmuneTech University of California, San Francisco	Phase 1
NCT04587687	Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma	Recurrent Follicular Lymphoma Refractory Follicular Lymphoma	Drug: Bendamustine Hydrochloride Drug: Brentuximab Vedotin	Joseph Tuscano National Cancer Institute (NCI) Seagen Inc. University of California, Davis	Phase 2
NCT04580771	A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial	Locally Advanced Cervical Squamous Cell Carcinoma, Not Otherwise Specified Stage IB3 Cervical Cancer FIGO 2018 Stage II Cervical Cancer FIGO 2018 Stage IIA Cervical Cancer FIGO 2018 Stage IIA1 Cervical Cancer FIGO 2018 Stage IIA2 Cervical Cancer FIGO 2018 Stage IIB Cervical Cancer FIGO 2018 Stage III Cervical Cancer FIGO 2018 Stage IIIA Cervical Cancer FIGO 2018 Stage IIIB Cervical Cancer FIGO 2018 Stage IIIC Cervical Cancer FIGO 2018 Stage IIIC1 Cervical Cancer FIGO 2018 Stage IIIC2 Cervical Cancer FIGO 2018 Stage IVA Cervical Cancer FIGO 2018	Drug: Cisplatin Biological: Liposomal HPV-16 E6/E7 Multi-peptide Vaccine PDS0101 Radiation: Radiation Therapy	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 2
NCT04578600	CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma	Indolent B-Cell Non-Hodgkin Lymphoma Recurrent B-Cell Non-Hodgkin Lymphoma Recurrent Chronic Lymphocytic Leukemia Recurrent Mucosa-Associated Lymphoid Tissue Lymphoma Recurrent Follicular Lymphoma Recurrent Hairy Cell Leukemia Recurrent Lymphoplasmacytic Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Refractory B-Cell Non-Hodgkin Lymphoma Refractory Chronic Lymphocytic Leukemia Refractory Mucosa-Associated Lymphoid Tissue Lymphoma Refractory Follicular Lymphoma Refractory Hairy Cell Leukemia Refractory Lymphoplasmacytic Lymphoma Refractory Mantle Cell Lymphoma Refractory Marginal Zone Lymphoma Recurrent Small Lymphocytic Lymphoma Refractory Small Lymphocytic Lymphoma	Drug: Lenalidomide Biological: Obinutuzumab Drug: Oral Azacitidine	Joseph Tuscano National Cancer Institute (NCI) Celgene University of California, Davis	Phase 1
NCT04570397	Ravulizumab and COVID-19	Covid19 Thrombotic Microangiopathies Acute Kidney Injury	Drug: Ravulizumab	Brigham and Women's Hospital	Phase 3
NCT04569461	Trimodality Approach to Localized Prostate Cancer: Pembrolizumab, ADT, and SBRT Followed by Prostatectomy	Prostate Cancer	Drug: pembrolizumab Radiation: Stereotactic body radiation therapy Drug: Short-term androgen deprivation therapy Procedure: Radical Prostatectomy	Bridget Koontz Merck Sharp & Dohme Corp. Duke University	Phase 2
NCT04566328	Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial	Plasma Cell Myeloma RISS Stage I Plasma Cell Myeloma RISS Stage II Plasma Cell Myeloma	Drug: Bortezomib Biological: Daratumumab and Hyaluronidase-fihj Drug: Dexamethasone Drug: Lenalidomide Other: Quality-of-Life Assessment	ECOG-ACRIN Cancer Research Group National Cancer Institute (NCI) Eastern Cooperative Oncology Group	Phase 3

해외 바이오의약품 임상 현황 (2020.10.26~2020.11.1)

한국바이오의약품협회, 2020.11.3
출처: ClinicalTrials.gov

NCT04558736	Haploidentical HCT for Severe Aplastic Anemia	Aplastic Anemia Bone Marrow Failure Syndrome Dyskeratosis Congenita	Drug: Anti-Thymocyte Globulin (Rabbit) Drug: Fludarabine Drug: Cyclophosphamide Drug: Mesna Drug: G-CSF Radiation: Total Lymphoid Irradiation (TLI) Device: CliniMACS Biological: HPC, A Infusion Biological: CD45RA-depleted DLI	St. Jude Children's Research Hospital	Phase 2
NCT04552886	Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma: Phase I Clinical Trial	Glioblastoma	Biological: TH-1 Dendritic Cell Immunotherapy	The Cooper Health System Baylor College of Medicine Philadelphia College of Osteopathic Medicine	Phase 1
NCT04543071	Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Patients With Pancreatic Adenocarcinoma	Pancreatic Cancer Adenocarcinoma of the Pancreas Adenocarcinoma	Drug: Motixafortide (BL-8040) Drug: Cemiplimab Drug: Gemcitabine Drug: Nab paclitaxel	Gulam Manji Regeneron Pharmaceuticals BioLine Rx Columbia University	Phase 2
NCT04526288	CPX-351 Versus Immediate Donor Stem Cell Transplant for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease	Acute Myeloid Leukemia Myelodysplastic Syndrome With Excess Blasts-2 Myeloid Neoplasm	Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Drug: Liposome-encapsulated Daunorubicin-Cytarabine	Fred Hutchinson Cancer Research Center Jazz Pharmaceuticals	Phase 2
NCT04510428	OSIG-eye Drops Treatment for Dry Eye Disease	Dry Eye	Drug: Ocular Surface Immune Globulin (OSIG) Drug: Placebo	Sandeep Jain, MD University of Illinois at Chicago	Phase 2
NCT04506554	A Study of Risk Enabled Therapy After Neoadjuvant Immunotherapy for Bladder Cancer	Muscle-Invasive Bladder Carcinoma	Drug: AMVAC + Nivolumab	Fox Chase Cancer Center	Phase 2
NCT04501094	A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma	Urothelial Cancer	Drug: Bintrafusp alfa (M7824)	National Cancer Institute (NCI) National Institutes of Health Clinical Center (CC)	Phase 2
NCT04498325	Evaluating the Effect of NT-17, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2 (COVID-19)	COVID-19 SARS-CoV-2	Drug: NT-17 Drug: Placebo Procedure: Blood for research purposes Procedure: Blood for pharmacokinetic samples Procedure: Nasopharyngeal, oropharyngeal, or saliva swab Procedure: Blood for anti-drug antibody (ADA)	Washington University School of Medicine Neolimmune Tech	Phase 1
NCT04496219	Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer	Bladder Urothelial Carcinoma In Situ Recurrent Bladder Urothelial Carcinoma Stage 0a Bladder Cancer AJCC v8 Stage 0is Bladder Cancer AJCC v8 Stage I Bladder Cancer AJCC v8 Superficial Bladder Urothelial Carcinoma	Device: Acupuncture Therapy Biological: BCG Solution Other: Best Practice Other: Quality-of-Life Assessment Other: Questionnaire Administration	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI)	Phase 2
NCT04493060	Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer	Metastatic Pancreatic Ductal Adenocarcinoma Stage IV Pancreatic Cancer AJCC v8	Biological: Dostarlimab Drug: Niraparib	Mayo Clinic National Cancer Institute (NCI)	Phase 2
NCT04477512	Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)	Metastatic Hormone Refractory Prostate Cancer	Drug: Cabozantinib Drug: Nivolumab Drug: Abiraterone acetate Drug: Prednisone Procedure: Peripheral blood collection	Washington University School of Medicine Bristol-Myers Squibb Exelixis	Phase 1
NCT04465643	Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor	Nerve Sheath Tumors	Drug: Nivolumab Drug: Ipilimumab	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bristol-Myers Squibb	Phase 1
NCT04450654	Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial)	Immune-Mediated Necrotizing Myopathy	Drug: Gamunex-C Drug: Albumin	University of Washington Grifols Biologicals, LLC	Phase 2
NCT04447768	The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)	Chronic Lymphocytic Leukemia (CLL)	Drug: Obinutuzumab Drug: Venetoclax	Memorial Sloan Kettering Cancer Center Genentech, Inc.	Phase 2
NCT04419909	Retreatment With CTL019/CTL119	Lymphoma, B-Cell	Drug: CD19 redirected autologous T cells (CTL019 or CTL119 cells)	Abramson Cancer Center of the University of Pennsylvania	Phase 1
NCT04401410	Anti-SARS Cov-2 T Cell Infusions for COVID 19	SARS-CoV 2 Viral Infection COVID 19	Biological: Dose Finding Phase (MTD) Biological: Partially HLA-matched SARS-CoV2s Other: Routine care (no SARS-CoV2s)	Baylor College of Medicine Center for Cell and Gene Therapy, Baylor College of Medicine The Methodist Hospital System AlloVir	Phase 1
NCT04375527	Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma	Clinical Stage III Cutaneous Melanoma AJCC v8 Clinical Stage IV Cutaneous Melanoma AJCC v8 Locally Advanced Cutaneous Melanoma Metastatic Cutaneous Melanoma Pathologic Stage III Cutaneous Melanoma AJCC v8 Pathologic Stage IIIA Cutaneous Melanoma AJCC v8 Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 Pathologic Stage IIID Cutaneous Melanoma AJCC v8 Pathologic Stage IV Cutaneous Melanoma AJCC v8 Unresectable Cutaneous Melanoma	Drug: Binimetinib Biological: Nivolumab Other: Questionnaire Administration	Jonsson Comprehensive Cancer Center	Phase 2
NCT04348747	Dendritic Cell Vaccines Against Her2/Her3, Cytokine Modulation Regimen, and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer	Anatomic Stage IV Breast Cancer AJCC v8 Metastatic Malignant Neoplasm in the Brain Metastatic Triple-Negative Breast Carcinoma Prognostic Stage IV Breast Cancer AJCC v8	Biological: Anti-HER2/HER3 Dendritic Cell Vaccine Drug: Celecoxib Biological: Pembrolizumab Biological: Recombinant Interferon Alfa-2b Drug: Rintatolimod	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 2

해외 바이오의약품 임상 현황 (2020.10.26~2020.11.1)

한국바이오의약품협회, 2020.11.3
출처: ClinicalTrials.gov

NCT04302324	A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab	Multiple Myeloma Refractory Multiple Myeloma Relapse Multiple Myeloma	Drug: Daratumumab Drug: Clarithromycin Drug: Pomalidomide Drug: Dexamethasone	Weill Medical College of Cornell University Janssen Scientific Affairs, LLC	Phase 2
NCT04301778	Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma	Unresectable Intrahepatic Cholangiocarcinoma	Drug: Durvalumab Drug: SNDX-6352	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Syndax Pharmaceuticals AstraZeneca	Phase 2
NCT04274166	Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum	Pyoderma Gangrenosum	Drug: secukinumab 150 mg (2 injections per dose)	Wake Forest University Health Sciences Novartis	Phase 2
NCT04230031	Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma	Multiple Myeloma	Drug: Daratumumab	Saad Z. Usmani, MD Janssen Research & Development, LLC Atrium Health	Phase 2
NCT04177810	Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer	Metastatic Pancreatic Cancer	Drug: Cemiplimab Drug: Plerixafor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Genzyme, a Sanofi Company American Association for Cancer Research	Phase 2
NCT04176380	RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma	Relapsed, Refractory Multiple Myeloma	Biological: RAPA-201 Autologous T cells	Rapa Therapeutics LLC Medical College of Wisconsin	Phase 2
NCT04144036	Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD)	Graft-versus-host Disease	Drug: Neihulizumab, 3 mg/kg Drug: Neihulizumab, 6 mg/kg Drug: Neihulizumab, 9 mg/kg Drug: Neihulizumab	Sameem M. Abedin, MD Medical College of Wisconsin	Phase 1
NCT04061980	Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer	BRAF NP_004324.2:p.V600M BRAF V600E Mutation Present Metastatic Thyroid Gland Carcinoma Refractory Thyroid Gland Carcinoma Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8 Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8 Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8	Drug: Binimetinib Drug: Encorafenib Biological: Nivolumab	Providence Health & Services	Phase 2
NCT04056910	Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors	Advanced Solid Tumor IDH1 Mutation Glioma	Drug: ivosidenib and nivolumab	Jason J. Luke, MD Agios Pharmaceuticals, Inc. Bristol-Myers Squibb University of Pittsburgh	Phase 2
NCT04038619	Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients	Colitis Diarrhea Malignant Genitourinary System Neoplasm	Procedure: Fecal Microbiota Transplantation Drug: Loperamide	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 1
NCT04006652	ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients	Acute Graft Versus Host Disease Haploidentical Hematopoietic Stem Cell Transplant	Drug: ApoGraft	Washington University School of Medicine Cellestis Biotechnology	Phase 1
NCT03943901	Split-Dose R-CHOP for Older Adults With DLBCL	Diffuse Large B Cell Lymphoma DLBCL Cancer	Drug: Rituximab Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristine Drug: Prednisone Biological: Pegfilgrastim	University of Wisconsin, Madison Medical College of Wisconsin	Phase 2
NCT03463239	Bioengineered Penile Tissue Constructs for Irreversibly Damaged Penile Corpora	Urologic Diseases Male Urogenital Diseases Penile Diseases Corpus Callosum Malformation Corpora Caverosa; Inflammation Trauma Injury	Biological: Autologous tissue engineered corpora	Wake Forest University Health Sciences United States Department of Defense	Phase 1
NCT03258658	Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures	Urologic Diseases Male Urogenital Diseases Urethral Stricture Urethral Injury	Biological: Autologous Engineered Urethral Construct	Wake Forest University Health Sciences United States Department of Defense	Phase 1
NCT04559230	Sacituzumab Govitecan in Recurrent Glioblastoma	Glioblastoma	Drug: Sacituzumab Govitecan	The University of Texas Health Science Center at San Antonio	Phase 2
NCT04551430	Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma	Metastatic Soft-tissue Sarcoma	Drug: Cabozantinib Drug: Nivolumab Drug: Ipilimumab	Washington University School of Medicine Exelixis Bristol-Myers Squibb	Phase 2
NCT04526509	Investigation of Autologous Enhanced T Cells in Advanced Tumors	Neoplasms	Drug: GSK3901961 Drug: GSK3845097 Drug: Fludarabine Drug: Cyclophosphamide	GlaxoSmithKline	Phase 1
NCT04344860	Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial	Von Willebrand Diseases Postpartum Hemorrhage	Drug: Recombinant Von Willebrand factor Drug: Tranexamic Acid Injection [Cyklokapron]	Margaret Ragni University of Pittsburgh	Phase 3
NCT04232657	Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI	Spinal Cord Injury (=3 Years) Sublesional Bone Loss Secondary to SCI	Drug: Romosozumab Drug: Denosumab Drug: Placebo	VA Office of Research and Development Kessler Institute for Rehabilitation	Phase 2
NCT03980769	Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders	Benign Neoplasm	Drug: Thiotepa Drug: Treosulfan Drug: Fludarabine Phosphate Biological: Rabbit Anti-Thymocyte Globulin Procedure: Allogeneic Hematopoietic Stem Cell Transplantation	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI) National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI)	Phase 2

해외 바이오의약품 임상 현황 (2020.10.26~2020.11.1)

한국바이오의약품협회, 2020.11.3
출처: ClinicalTrials.gov

NCT03768310	CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA)	Non-hodgkin Lymphoma Acute Lymphoblastic Leukemia	Biological: CD19.CAR-multiVST for Group A Biological: CD19.CAR-multiVST for Group B	Baylor College of Medicine The Methodist Hospital System Center for Cell and Gene Therapy, Baylor College of Medicine	Phase 1
NCT04604899	Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa	Retinitis Pigmentosa	Biological: human retinal progenitor cells	jCyte, Inc California Institute for Regenerative Medicine (CIRM)	Phase 2
NCT04601857	Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma	Advanced and Metastatic Urothelial Cancer	Drug: Futibatinib and Pembrolizumab	Taiho Oncology, Inc Merck Sharp & Dohme Corp.	Phase 2
NCT04549285	Infusions of Mesenchymal Stromal Cells in Children With Multisystem Inflammatory Syndrome	Multisystem Inflammatory Syndrome in Children	Biological: Human Cord Tissue Mesenchymal Stromal Cells (hCT-MSCs)	Joanne Kurtzberg, MD Duke University	Phase 1
NCT04426591	Red Blood Cell Survival in Sickle Cell Disease	Sickle Cell Disease	Drug: Biotin Labeled Red Blood Cells	Emory University National Heart, Lung, and Blood Institute (NHLBI)	Phase 1
NCT03792360	Adipose Derived SVF for Aero-digestive Fistulae	Tracheoesophageal Fistula Bronchoesophageal Fistula Tracheal Fistula	Drug: SVF (Stromal Vascular Fraction)	Mayo Clinic	Phase 1
NCT04539938	A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer	Breast Cancer	Drug: tucatinib Drug: trastuzumab deruxtecan	Seagen Inc.	Phase 2
NCT04270175	Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab	Amyloid AL Amyloidosis Refractory AL Amyloidosis	Drug: Daratumumab Drug: Pomalidomide Drug: Dexamethasone	Weill Medical College of Cornell University Janssen Scientific Affairs, LLC	Phase 2
NCT04498910	A Study of LY3451838 in Participants With Migraine	Migraine	Drug: LY3451838 Drug: Placebo	Eli Lilly and Company	Phase 2
NCT04594642	A Study of TNB-486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	B-cell Non Hodgkin Lymphoma Diffuse Large B Cell Lymphoma High-grade B-cell Lymphoma Follicular Lymphoma	Drug: TNB-486	Teneobio, Inc.	Phase 1
NCT04432207	A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer	Non Small Cell Lung Cancer Non Small Cell Lung Cancer Stage IIIB Non-small Cell Lung Cancer Stage IV Squamous Non-small-cell Lung Cancer Large Cell Carcinoma Lung Adenocarcinoma Lung	Drug: IMU-201 (administered as PD1-Vaxx) Drug: Standard of care treatment for NSCLC	Imugene Limited	Phase 1
NCT04599972	An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2)	Presbyopia	Drug: CSF-1 Drug: Vehicle	Orasis Pharmaceuticals Ltd.	Phase 3
NCT04589845	Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study	Solid Tumors	Drug: Entrectinib Drug: Alectinib Drug: Atezolizumab Drug: Ipatasertib Drug: Trastuzumab emtansine Drug: Idasanutlin Drug: GDC-0077	Hoffmann-La Roche	Phase 2
NCT04544449	A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis	Multiple Sclerosis, Primary Progressive	Drug: fenebrutinib Drug: ocrelizumab Drug: placebo	Hoffmann-La Roche	Phase 3
NCT04540185	A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19	Covid19 SARS (Severe Acute Respiratory Syndrome) SARS-CoV Infection SARS-CoV-2	Biological: Biological: oral polio vaccine Biological: Comparable Placebo Drug: NA-831 Drug: Comparable Placebo of drug Combination Product: Combination of oral polio vaccine and NA-831 Combination Product: Comparable Placebo of Oral Polio Vaccine and Placebo of drug	NeuroActiva, Inc Biomed Industries, Inc.	Phase 3
NCT04457284	Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer	Colorectal Adenocarcinoma	Drug: Temozolomide (TMZ) Drug: Cisplatin Drug: Nivolumab	Memorial Sloan Kettering Cancer Center Bristol-Myers Squibb	Phase 2
NCT04338581	Evaluation of AMG 714 for Vitiligo	Vitiligo	Biological: AMG 714 Biological: Placebo Procedure: nbUVB phototherapy	National Institute of Allergy and Infectious Diseases (NIAID) Immune Tolerance Network (ITN) PPD Rho Federal Systems Division, Inc Amgen	Phase 2
NCT04416451	Study of Rituximab and Venetoclax in People With Newly Diagnosed Marginal Zone Lymphoma	Marginal Zone Lymphoma	Drug: Rituximab Drug: Venetoclax	Memorial Sloan Kettering Cancer Center AbbVie	Phase 2
NCT04434196	A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Lymphoma, Non-Hodgkin	Drug: CC-99282 Drug: Obinutuzumab	Celgene	Phase 1
NCT04515394	Study of Tepotinib Combined With Cetuximab in Participants Left-Sided Metastatic Colorectal Cancer (mCRC) Acquired Resistance Due to Mesenchymal Epithelial Transition (MET) Amplification	Colorectal Neoplasms	Drug: Tepotinib Biological: Cetuximab	EMD Serono Research & Development Institute, Inc Merck KGaA, Darmstadt, Germany EMD Serono	Phase 2

해외 바이오의약품 임상 현황 (2020.10.26~2020.11.1)

한국바이오훼약품협회, 2020.11.3
출처: ClinicalTrials.gov

○ 영국 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04443829	Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma	Primary CNS Lymphoma	Biological: CD19CAR T-cells	University College, London	Phase 1
NCT04607850	Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions	HPV	Biological: ChAdOx1-HPV Biological: MVA-HPV Biological: Placebo	Vaccitech Limited	Phase 1 Phase 2
NCT04515394	Study of Tepotinib Combined With Cetuximab in Participants Left-Sided Metastatic Colorectal Cancer (mCRC) Acquired Resistance Due to Mesenchymal Epithelial Transition (MET) Amplification	Colorectal Neoplasms	Drug: Tepotinib Biological: Cetuximab	EMD Serono Research & Development Institute, Inc. Merck KGaA, Darmstadt, Germany EMD Serono	Phase 2

○ 프랑스 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04577638	Accelerated Radio-Immunotherapy for Lung Cancer	Non Small Cell Lung Cancer Stage III	Combination Product: Nivolumab and Intensity Modulated Radiotherapy (IMRT)	Center Eugene Marquis Bristol-Myers Squibb	Phase 2
NCT04602377	Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT	Small Cell Ovarian Carcinoma	Drug: Pembrolizumab 25 MG/ML [Keytruda]	ARCAGY/ GINECO GROUP Merck Sharp & Dohme Corp.	Phase 2
NCT04515394	Study of Tepotinib Combined With Cetuximab in Participants Left-Sided Metastatic Colorectal Cancer (mCRC) Acquired Resistance Due to Mesenchymal Epithelial Transition (MET) Amplification	Colorectal Neoplasms	Drug: Tepotinib Biological: Cetuximab	EMD Serono Research & Development Institute, Inc. Merck KGaA, Darmstadt, Germany EMD Serono	Phase 2

○ 독일 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04602533	Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)	Small Cell Lung Cancer Limited Stage	Drug: Durvalumab Drug: standard of care	Michael Hopp AstraZeneca Johannes Gutenberg University Mainz	Phase 2
NCT04057261	Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease	Type 2 Diabetes Cardiovascular Diseases	Drug: Liraglutide Pen Injector [Victoza] Drug: Placebo	RWTH Aachen University Novo Nordisk A/S	Phase 3
NCT04589845	Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study	Solid Tumors	Drug: Entrectinib Drug: Alectinib Drug: Atezolizumab Drug: Ipatasertib Drug: Trastuzumab emtansine Drug: Idasanutlin Drug: GDC-0077	Hoffmann-La Roche	Phase 2

○ 중국 14건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04606303	A Single-center, Prospective, Single-arm Phase7췔rial of Neoadjuvant Toripalimab Plus Platinum-doublet Chemotherapy (Chemo) in Locally Advanced NSCLC.	Locally Advanced NSCLC	Drug: Toripalimab combination with platinum-containing dual-drug chemotherapy.	Beijing Cancer Hospital	Phase 1 Phase 2
NCT04560894	SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma	Hepatocellular Carcinoma	Drug: SCT-I10A Drug: SCT510 Drug: Sorafenib 200mg	Sinocelltech Ltd.	Phase 2 Phase 3
NCT04460066	A Study of Anti-PD-L1 Antibody in Perioperative Chemotherapy of Esophageal Carcinoma.	Esophageal Cancer	Drug: anti-PD-L1 antibody Drug: albumin bound paclitaxel Drug: cisplatin Drug: placebo Procedure: radical resection of esophageal carcinoma	Lee's Pharmaceutical Limited	Phase 1 Phase 2
NCT04606433	A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Non-Hodgkin Lymphoma	Non-hodgkin Lymphoma	Drug: GNC-038	Sichuan Baili Pharmaceutical Co., Ltd. SystImmune Inc.	Phase 1
NCT04594135	Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies	T-cell Acute Lymphoblastic Leukemia T-cell Non-Hodgkin Lymphoma	Drug: anti-CD5 CAR T cells	iCell Gene Therapeutics iCAR Bio	Phase 1
NCT04592458	Safety and Efficacy Evaluation of ̢-globin Restored Autologous Hematopoietic Stem Cells in ̢-thalassemia Major Patients	̢-Thalassemia Major	Biological: ̢-globin restored autologous HSC	BGI-research Shenzhen Children's Hospital	Phase 1
NCT04517526	Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study	Lung Cancer Stage IV , EGFR-mutant , TKI , PD-L1 , SBRT	Drug: pemetrexed , cisplatin/carboplatin , bevacizumab , durvalumab , SBRT	Shanghai Cancer Hospital, China	Phase 2
NCT04514835	A Phase II Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC	Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma	Drug: Cisplatin+Capecitabine+Sintilimab	The First Affiliated Hospital of Zhengzhou University	Phase 2
NCT04176913	Study of LUCAR-20S in Patients With R/R NHL	Diffuse Large B Cell Lymphoma Follicular Lymphoma Mantle Cell Lymphoma Small Lymphocytic Lymphoma	Drug: LUCAR-20S CAR-T cells	The First Affiliated Hospital with Nanjing Medical University Nanjing Legend Biotechnology Co.,Ltd.	Phase 1
NCT04590599	A Clinical Study of Sintilimab Independently or in Combination With IBI310 (Anti-CTLA4) in Second-Line Cervical Cancer	Advanced Cervical Cancer	Drug: IBI310+sintilimab Drug: Placebo+sintilimab	Innovent Biologics (Suzhou) Co. Ltd.	Phase 2
NCT04550624	Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Cholangiocarcinoma	Advanced Cholangiocarcinoma	Drug: Pembrolizumab Injection [Keytruda] Drug: Lenvatinib Mesylate	Shanghai Jiahui International Hospital Shanghai Zhongshan Hospital	Phase 2

해외 바이오의약품 임상 현황 (2020.10.26~2020.11.1)

한국바이오의약품협회, 2020.11.3
출처: ClinicalTrials.gov

NCT04518280	The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Locally Advanced Rectal Cancer	Locally Advanced Rectal Cancer	Drug: PD-1 antibody Drug: Capecitabine Drug: Oxaliplatin Radiation: Short-course radiotherapy	Fudan University	Phase 2
NCT04586478	Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma	Non-Hodgkin's Lymphoma	Biological: single dose of CNCT19	Juventas Cell Therapy Ltd.	Phase 2
NCT04589845	Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study	Solid Tumors	Drug: Entrectinib Drug: Alectinib Drug: Atezolizumab Drug: Ipatasertib Drug: Trastuzumab emtansine Drug: Idasanutlin Drug: GDC-0077	Hoffmann-La Roche	Phase 2

○ 일본 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04417192	Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer	Ovarian Cancer	Drug: Olaparib Drug: Pembrolizumab	National Cancer Center Hospital East Merck Sharp & Dohme Corp.	Phase 2